Savara Inc Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31)
Savara Inc (SVRA) had Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) of $1.40 million as of 2011-06-30, per its 10-Q filed 2011-08-08.
Discontinued › Notes › Business Combinations
us-gaap:BusinessAcquisitionContingentConsiderationAtFairValue · last filed 2011-08-08
- 2011-06-30: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $1.40M.
- 2010-12-31: Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) $0.00.
| Period end | Business Acquisition, Contingent Consideration, at Fair Value (Deprecated 2013-01-31) |
|---|---|
| 2011-06-30 | $1.40M 10-Q · filed 2011-08-08 |
| 2010-12-31 | $0.00 10-Q · filed 2011-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| Corvus Pharmaceuticals, Inc. (CRVS) | United States | $0.994B | -23.25 |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Kura Oncology, Inc. (KURA) | United States | $0.967B | -3.29 |
| Arbutus Biopharma Corp (ABUS) | $0.965B | 6.19 | |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B |